Clinical trials: Plasma Cell Disorders
Hematologic Diseases, Cachexia; Cancer
WB-EMS and Nutrition in Patients With Hematological Malignancies
This study evaluates the effects of a whole-body electromyostimulation (WB-EMS) training combined with individualized nutritional support on skeletal muscle mass, body composition, muscle strength/function, quality of life…
- Conditions
- Hematologic Diseases, Cachexia; Cancer, Leukemia, Myeloma
- Trial name
- NCT03556748
- Testing
- whole-body electromyostimulation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy is a rapidly developing novel approach in adoptive immunotherapy for tumors in recent years.
- Conditions
- Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
- Trial name
- NCT07034755
- Testing
- autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Multiple Myeloma, Renal Impairment
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and…
- Trial name
- POM Renal (NCT01575925)
- Testing
- 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Celgene
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Relapsed Multiple Myeloma
Non-interventional Study on Salvage Auto in Relapsed Myeloma
Multiple myeloma (MM) is an incurable disease that is characterized by the accumulation of clonal plasma cells in the bone marrow.
- Trial name
- IFM-2015-03 (NCT02439476)
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
Multiple Myeloma
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and…
- Trial name
- NCT01109004
- Testing
- Lenalidomide, lenalidomide, bortezomib and dexamethasone
- Where
- 54 sites in United States
- Volunteers
- 758 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma, Plasma Cell Disorder
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
- Trial name
- NCT04879043
- Testing
- HDP-101
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 78 people
- Sponsor
- Heidelberg Pharma AG
Multiple Myeloma
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
The purpose of this study is to provide oral panobinostat (PAN) treatment to relapsed or relapsed and refractory multiple myeloma patients who are without satisfactory treatment alternatives prior to the commercial availability*…
- Trial name
- NCT02568943
- Testing
- Panobinostat
- Where
- 40 sites in Austria, Canada and 4 more
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
The purpose of this study is to provide bortezomib to patients with multiple myeloma who have received at least 2 previous lines of therapy and are refractory or have relapse after their last treatment.
- Trial name
- NCT00440635
- Testing
- Bortezomib, tradename Velcade
- Volunteers
- 641 people
- Sponsor
- Janssen-Cilag International NV
Relapsed/Refractory Multiple Myeloma
A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators…
- Trial name
- NCT07558915
- Testing
- RO7851624
- Where
- Australia
- Volunteers
- 160 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma…
- Trial name
- NCT05827016
- Testing
- Iberdomide, Lenalidomide
- Where
- 269 sites in United States, Argentina and 32 more
- Volunteers
- 1,230 people
- Sponsor
- Bristol-Myers Squibb
Mantle Cell Lymphoma, B Cell Lymphoma
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma.
- Conditions
- Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT01148108
- Testing
- Canfosfamide HCl for injection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Telik
Multiple Myeloma
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can…
- Trial name
- LINKER-MM1 (NCT03761108)
- Testing
- Linvoseltamab
- Where
- 40 sites in United States, Belgium and 5 more
- Volunteers
- 387 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoproliferative Disorder, Multiple Myeloma
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric…
- Trial name
- NCT06630104
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Multiple Myeloma
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
This is a phase II, open label, single-center study of ultra-high dose dexamethasone administered intravenously and orally as monotherapy for the treatment of relapsed multiple myeloma.
- Trial name
- UltraDex (NCT02402725)
- Testing
- Dexamethasone
- Where
- United States
- Sponsor
- Boston Medical Center
Cancer and Chemotherapy Related Anemia, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Augmented Virtual Reality for Reducing Pain, Stress, Anxiety and Improve Self Efficacy in Adult Cancer Patients Undergoing Chemotherapy in The West Bank
The main purpose of this study is to examine the effect of using AVR on pain, stress, anxiety, and SE among adult cancer patients undergoing chemotherapy in the West Bank hospitals in Palestine.
- Trial name
- AVR-CHEMO (NCT07152938)
- Testing
- AVR Group (Chemotherapy + AVR)
- Where
- 3 sites in Palestinian Territories
- Volunteers
- 150 people
- Sponsor
- Arab American University (Palestine)
Multiple Myeloma
Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial
Oral and intestinal mucositis are major risk factors for the occurrence of fever during neutropenia and bloodstream infections after intensive chemo- and radiotherapy.
- Trial name
- AFFECT-2 (NCT04099901)
- Testing
- Anakinra
- Where
- 3 sites in Netherlands
- Volunteers
- 88 people
- Sponsor
- Radboud University Medical Center
Multiple Myeloma
Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
The main objective of this study is to assess the efficacy of SCIOS-469 as monotherapy in relapsed, refractory patients with multiple myeloma (MM), based on response rates.
- Trial name
- NCT00087867
- Testing
- SCIO-469, SCIO-469 and bortezomib
- Volunteers
- 62 people
- Sponsor
- Scios, Inc.
Fatigue, Leukemia
Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation
Physiological changes caused by hematological diseases associated with high dose chemotherapy have a negative impact on patient's functionality, making them more fragile and vulnerable after hematopoietic cell transplantation.
- Conditions
- Fatigue, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT04496011
- Testing
- Aerobic training with cycle ergometer
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Federal University of Health Science of Porto Alegre